Australia
Austria
Belgium
Brazil
China
Colombia
Costa Rica
Denmark
France
Germany
Greece
Hungary
India
Italy
Japan
Mexico
Netherlands
New Zealand
Norway
Philippines
Poland
Portugal
South Africa
South Korea
Spain
Sweden
Switzerland
Taiwan
Thailand
United Kingdom
United States
Uruguay
Vietnam
Financial public releases
2020 fourth quarter consolidated sales
2021/01/19 - Financial public releases
2020 annual revenue shows strong growth of +5.7% at constant exchange rates and scope (+3.2% at constant rates)
2020 third quarter consolidated sales
2020/10/14 - Financial public releases
Revenue grew +6.8% at constant exchange rates and scope at the end of September 2020 (+5.6% at constant rates) thanks to solid third quarter performance
Virbac governance evolution
2020/10/13 - Financial public releases
Virbac will change its governance at its shareholders' meeting on December 15
2020 half year results
2020/09/16 - Financial public releases
Operating profit from ordinary activities up sharply for the first half of 2020 reflecting revenue resiliency and strong expenditure restraint during the Covid-19 crisis
2020 second quarter consolidated sales
2020/07/20 - Financial public releases
Revenue grew by +5.0% at constant exchange rates in the first half of 2020 (+4.5% excluding Sentinel), impacted by a decline in the second quarter of the year
Divestment of US rights
2020/07/02 - Financial public releases
Virbac completes divestment of U.S. Rights to SENTINEL® brands to MSD Animal Health
Signing of an agreement
2020/05/13 - Financial public releases
Virbac to divest U.S. Rights to SENTINEL® brands to MSD Animal Health
2020 first quarter consolidated sales
2020/04/15 - Financial public releases
2020 first quarter revenue rose by +14.3% at comparable exchange rates, significantly impacted by anticipatory buying
2019 annual results
2020/03/16 - Financial public releases
2019 operating profit from ordinary activities on the rise
2019 Annual consolidated sales
2020/01/16 - Financial public releases
2019 annual revenue shows strong growth of +6.6% at constant exchange rates
2019 third quarter consolidated sales
2019/10/11 - Financial public releases
Solid +8.4% growth in revenue at constant exchange rates at the end of September, 2019
Stock exchange: Virbac again in the SBF 120
2019/09/19 - Financial public releases
Following the quarterly review of its indices, the Paris stock exchange operator, Euronext, includes Virbac in the CAC Mid 60 and SBF 120 as from 23 September.
2019 half year results
2019/09/16 - Financial public releases
Operating profit on the rise in the first half of 2019
Cyrille Petit appointed as a member of the Virbac supervisory board
2019/07/18 - Financial public releases
Virbac announces the arrival of Cyrille Petit as a member of the supervisory board as of June 18, 2019. In addition, on the audit committee he will replace Olivier Bohuon, who is also a member of the supervisory board.
2019 second quarter consolidated sales
2019/07/16 - Financial public releases
2019 first half-year revenue grew by +6.6% at constant exchange rates
2019 first quarter consolidated sales
2019/04/11 - Financial public releases
2019 first quarter revenue rose by +10.9% at comparable exchange rates
2018 annual results
2019/03/18 - Financial public releases
2018 operating profit from ordinary activities grew by 13.4%
2018 Annual consolidated sales
2019/01/17 - Financial public releases
2018 annual revenue grew by +4.5% at constant exchange rates
2018 third quarter consolidated sales
2018/10/11 - Financial public releases
Revenue grew by +5.5% at constant exchange rates at the end of September 2018
2018 half year results
2018/09/17 - Financial public releases
Operating profit up sharply in the first half of 2018
2018 second quarter consolidated sales
2018/07/17 - Financial public releases
Revenue grew by +4.3% at constant exchange rates in the second quarter of 2018
2018 first quarter consolidated sales
2018/04/12 - Financial public releases
2018 first quarter revenue rose by +3.3% at comparable exchange rates
2017 annual results
2018/03/14 - Financial public releases
Operating profit from ordinary activities 2017 comparable to 2016
2017 Annual consolidated sales
2018/01/16 - Financial public releases
Annual sales comparable to 2016 at constant exchange rates after strong fourth-quarter growth
Aquaculture: Virbac postpones its option to buy Centrovet for three years
2017/11/22 - Financial public releases
By mutual agreement, Virbac and the other shareholders of Centrovet have decided to postpone the option to buy the Chilean aquaculture specialist for three years, under the same pricing conditions.
2017 third quarter consolidated sales
2017/10/12 - Financial public releases
Virbac: quarterly sales affected by distributor destocking in the United States
Virbac group: Solène Madelpuech joins the supervisory board
2017/09/22 - Financial public releases
On September 5, 2017, Virbac’s supervisory board co-opted Solène Madelpuech into the supervisory board as a new member. On the same day, Jeanine Dick, aged 81, announced her resignation.
2017 half year results
2017/09/11 - Financial public releases
Slight increase in first half results
2017 second quarter consolidated sales
2017/07/17 - Financial public releases
Virbac: second quarter sales growth largely offsets the decline in the first quarter
2017 first quarter consolidated sales
2017/04/12 - Financial public releases
First quarter 2017 sales down, strongly impacted by stock effects in the distribution in the United States
2016 annual results
2017/03/13 - Financial public releases
Strong rebound in profitability in 2016
2016 Annual consolidated sales
2017/01/17 - Financial public releases
Annual sales growth of 4.5%, at constant exchange rates
St. Louis: lifting of the Warning Letter for the Virbac production site
2016/12/16 - Financial public releases
Virbac announces that it has received from the Food and drug administration (FDA) a communication confirming the lifting of the Warning Letter received in December 2015 for its St. Louis production site (Missouri, USA).
2016 third quarter consolidated sales
2016/10/13 - Financial public releases
Sales grow by 3.2% at the end of September at constant rates
2016 second quarter consolidated sales
2016/07/18 - Financial public releases
Sales growth by 3.6% at constant exchange rates in the first half
2016 first quarter consolidated sales
2016/04/13 - Financial public releases
Sales in the first quarter 2016 : return to organic growth
2015 annual results
2016/03/14 - Financial public releases
2015 annual results heavily impacted by the United States
2015 Annual consolidated sales
2016/01/14 - Financial public releases
Annual sales growth of 10.2%, driven by exchange rates and acquisitions
2015 third quarter consolidated sales
2015/10/15 - Financial public releases
Virbac : sales grow by 5.5% in the third quarter
2015 half year results
2015/09/15 - Financial public releases
Half-year results heavily impacted by the United States
2015 second quarter consolidated sales
2015/07/16 - Financial public releases
Virbac : sales grow by 18.1% in the first half
Group's perspectives for 2015 impacted by the industrial situation in the United-States
2015/06/23 - Financial public releases
Group’s perspectives for 2015 impacted by the industrial situation in the United-States
2015 first quarter consolidated sales
2015/06/15 - Financial public releases
Sales growth of 17.1% in the first quarter
PEA-PME eligibility of Virbac
2015/03/24 - Financial public releases
Virbac, listed on Euronext Paris
2014 annual results
2015/03/16 - Financial public releases
Results grow in 2014 following a strong second half
2014 Annual consolidated sales
2015/01/15 - Financial public releases
Sustained growth in the fourth quarter
Virbac announces the closing of the SENTINEL® brands family acquisition in the United States
2015/01/05 - Financial public releases
Virbac announces the successful closing on January 2nd of its agreement with Eli Lilly and Company to acquire two major parasiticides for dogs in the United States: SENTINEL® Flavor Tabs® and SENTINEL® SPECTRUM®, marketed up to now by Novartis Animal Health.
Virbac agrees to acquire veterinary assets from Eli Lilly in the United States
2014/10/27 - Financial public releases
Virbac announces that it has entered into an agreement with Eli Lilly and Company to acquire major United States veterinary products currently marketed by Novartis Animal Health. Eli Lilly has agreed to divest these U.S. assets in connection with the U.S. Federal Trade Commission’s review of Eli Lilly’s pending acquisition of Novartis Animal Health worldwide.
2014 third quarter consolidated sales
2014/10/16 - Financial public releases
Confirmation of the rebound of growth in the third quarter
2014 half year results
2014/08/29 - Financial public releases
Half-year results impacted by foreign exchange and the low level of activity in the United States
2014 second quarter consolidated sales
2014/07/17 - Financial public releases
Organic growth of 3% in the first half
Annual report 2013 available
2014/04/30 - Financial public releases
- download HERE (or in Investors > Financial reports > 2013);
- or on request, under legal and regulatory conditions.
PEA-PME eligibility of Virbac
2014/04/23 - Financial public releases
2014 first quarter consolidated sales
2014/04/15 - Financial public releases
2013 annual results
2014/03/19 - Financial public releases
Current operating profit increases by 6.9% in 2013
2013 Annual consolidated sales
2014/01/16 - Financial public releases
Rebound of growth in the last quarter
2013 third quarter consolidated sales
2013/10/17 - Financial public releases
Slight rebound of organic growth in the third quarter
2013 half year results
2013/08/30 - Financial public releases
Slight increase of the current operating profit in the first half of 2013
2013 second quarter consolidated sales
2013/07/18 - Financial public releases
Sales growth of 9.4% in the second quarter
2013 first quarter consolidated sales
2013/04/16 - Financial public releases
Sales growth of 3.6% in the first quarter
2012 annual results
2013/03/11 - Financial public releases
A 15.8% net profit increase in 2012
2012 annual consolidated sales
2013/01/17 - Financial public releases
Sales growth of 11.5% in 2012
Virbac becomes a leader of the Aquaculture Health Market
2012/11/23 - Financial public releases
2012 third quarter consolidated sales
2012/10/18 - Financial public releases
2012 half year results
2012/08/31 - Financial public releases
2012 second quarter consolidated sales
2012/07/19 - Financial public releases
2012 acquisition
2012/06/25 - Financial public releases
2012 first quarter consolidated sales
2012/04/18 - Financial public releases